Back to today’s briefing

Story perspectives

Korean Firms Race to Capture $150 Billion Obesity Market

8/5/2025

41 4

Summary

Story summary

Korean pharmaceutical companies are racing to create alternatives to popular weight-loss drugs, with Hanmi Pharmaceutical at the forefront, set to launch its once-weekly GLP-1 shot, Efpeglenatide, in 2025. Competitors like HK Inno. N and Yuhan are also making strides. The global obesity medication market is projected to skyrocket from $15 billion to an astonishing $150 billion by 2035.

1 of 1

Story summary

Korean pharmaceutical companies are racing to create alternatives to popular weight-loss drugs, with Hanmi Pharmaceutical at the forefront, set to launch its once-weekly GLP-1 shot, Efpeglenatide, in 2025. Competitors like HK Inno. N and Yuhan are also making strides. The global obesity medication market is projected to skyrocket from $15 billion to an astonishing $150 billion by 2035.